US Patent

US8415362 — Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

Composition of Matter · Assigned to Incyte Corp · Expires 2027-12-24 · 2y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a class of compounds, specifically heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines, that inhibit Janus kinases.

USPTO Abstract

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines of Formula I: that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Drugs covered by this patent

Patent Metadata

Patent number
US8415362
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-12-24
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.